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Abstract
Background and Aims Glycemic control in geriatric
patients with type 2 diabetes (T2DM) remains clinically
challenging. The objective of this study was to compare the
safety and efficacy of insulin lispro in patients C65 years
(geriatric) to those\65 years (non-geriatric), using a meta-
analysis of randomized controlled clinical trials (RCT).
Methods This is a retrospective analysis of predefined
endpoints from an integrated database of seven RCTs of
T2DM patients treated with insulin lispro. The primary
efficacy measure tested the non-inferiority of insulin lispro
(geriatric vs. non-geriatric; non-inferiority margin 0.4 %)
in terms of hemoglobin A1c (HbA1c) change from baseline
to Month 3 (N = 1,525), with change from baseline to
Month 6 as a supportive analysis (N = 885). Changes in
HbA1c from baseline were evaluated with an analysis of
covariance model. Secondary measures included incidence
and rate of hypoglycemia, and incidence of cardiovascular
events.
Results Mean change in HbA1c from baseline to Month 3
was similar for geriatric (-0.97 %) and non-geriatric
patients (-1.05 %); least-square (LS) mean difference
(95 % CI) was 0.02 % (-0.11, 0.15 %; p = 0.756). Sim-
ilar results were observed in patients treated up to Month 6;
LS mean difference (95 % CI) was 0.07 % (-0.12,
0.26 %; p = 0.490). Decrease in HbA1c from baseline to
Months 3 and 6 was non-inferior in geriatric compared
with non-geriatric patients. There were no significant dif-
ferences in the incidence and the rate of hypoglycemia,
incidence of cardiovascular events, or other serious adverse
events including malignancy, post-baseline between the
two cohorts.
Conclusion Key measures of efficacy and safety in geri-
atric patients with T2DM were not significantly different
from non-geriatric patients when utilizing insulin lispro.
Insulin lispro may be considered a safe and efficacious
therapeutic option for the management of T2DM in geri-
atric patients.
Keywords Insulin lispro  Type 2 diabetes 
Geriatric  Hypoglycemia
Introduction
The burden of type 2 diabetes on geriatric patients is an
important public health issue. According to the American
Diabetes Association (ADA), it was estimated that
approximately 26.9 % (*10.9 million) of US residents
aged 65 years or older had diabetes, of which *390,000
were newly diagnosed [1].
While ADA guidelines do not have a specific target
recommendation for geriatric patients and contemplate
individualization of hemoglobin (Hb) A1c (HbA1c) goals
for many non-pregnant adults with diabetes [2], American
Geriatric Society (AGS) guidelines suggest a target of
8.0 % in frail geriatric patients with diabetes [3]. The
principles of blood glucose control are essentially the same
in geriatric patients compared to middle-aged adult
patients; however, achievement of glycemic control is
often complicated by many factors in geriatric patients.
Age-related decline in physical and cognitive functions,
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difficulty in achieving dietary and exercise goals, presence
of multiple comorbidities, polypharmacy and increased risk
for adverse events are some of the factors noted [4].
This meta-analysis was undertaken using data from
seven randomized controlled trials (RCTs) of patients with
type 2 diabetes treated with insulin lispro to test the
hypothesis that the use of insulin lispro in patients
C65 years of age is as safe and efficacious to use as it is in
patients\65 years of age, as measured by change in HbA1c
and rates of hypoglycemia.
Methods
Selection criteria and characteristics of clinical studies
An integrated database of RCTs was created using pre-
specified criteria from a pool of 18 RCTs using insulin
lispro conducted by Eli Lilly and Company. Studies were
included only if they met the following inclusion criteria:
(1) studies were global in nature and had patient-level data
available for inclusion in the analysis; (2) the study pop-
ulation consisted of patients with type 2 diabetes; (3) there
was an insulin lispro treatment arm(s) with a treatment
period of at least 3 months duration; and (4) HbA1c was
measured at baseline (before the study drug was adminis-
tered) and at least once post-baseline (after the study drug
was administered).
The two age cohorts were defined based on patient ages
at randomization; the geriatric cohort included patients
C65 years of age and the non-geriatric cohort included
patients \65 years of age. Non-inferiority of geriatric
cohort to non-geriatric cohort in terms of HbA1c change
from baseline to the endpoint (3 and 6 months of treat-
ment) was considered confirmed with a non-inferiority
margin of 0.4 %. This was established if the lower limit of
the 95 % confidence interval (CI) of the difference in
HbA1c change between the two age cohorts (non-geriatric
cohort minus geriatric cohort) was[-0.4 %, based on data
for up to 3 and 6 months of treatment. This non-inferiority
margin is similar to that used in other treat-to-target studies
[5–7]. Secondary objectives included an assessment of the
overall incidence and rates of hypoglycemia (all patient-
reported events) and cardiovascular event incidence in an
HbA1c-matched cohort, based on data for up to 3 and
6 months of treatment. See the ‘‘Results’’ section for
detailed definitions of hypoglycemia used in studies
included in the meta-analysis.
Statistical methodology
Statistical analyses of the primary and secondary end-
points were performed in accordance with a pre-specified
statistical analysis plan based on a modified intent-to-treat
(ITT) population with patients who had at least one dose
of study insulin and age information available. The last
observation carried forward (LOCF) method was used to
replace missing values. The primary analyses were per-
formed on the ITT population combining all seven studies
with C3 months of insulin lispro treatment. HbA1c change
from baseline was evaluated with an analysis of covari-
ance (ANCOVA) model that contained baseline HbA1c as
a covariate and age cohort (geriatric vs. non-geriatric),
study, country (grouped by region: North America, Asia,
Africa, and Europe) and basal insulin, use (yes or no) as
factors. A study factor was included in all analysis models
to adjust for imbalances noted at baseline. Results from
the above analyses are presented under headings of ‘‘All
Studies Combined’’. The supportive analyses were per-
formed on the ITT population combining four studies with
C6 months of insulin lispro treatment. Results from sup-
portive analyses are presented under headings of ‘‘Long-
term Studies Combined’’. Sensitivity analyses that exclu-
ded patients with extreme HbA1c values (HbA1c \4.5 %,
or HbA1c [15 %) were conducted at baseline, Month 3,
and/or at Month 6. These sensitivity analyses showed
similar results to that of the whole population and
accordingly these patients were included in the full
analysis. The rates of all patient-reported hypoglycemia
(episodes/patient/30 days) were compared between the
age cohorts with a non-parametric ranked analysis of
variance (ANOVA) model that contained age cohort,
study, and country as factors. In addition to the ranked
ANOVA model, a negative binomial model was used as a
supportive model for analyzing the number of episodes
and was performed for each analysis with the same factors
as in the ranked ANOVA model. The incidence of
hypoglycemia was analyzed with logistic regression
models containing age cohort, study, and country as fac-
tors. Since renal function can influence the incidence of
hypoglycemia, an analysis was performed including data
from four studies that had plasma creatinine data available
and patients with impaired renal function (defined as
glomerular filtration rate (GFR) \60 mL/min/1.73 m2).
Insulin dose was analyzed with an ANOVA model that
contained age cohort, study, and country. No adjustments
for multiplicity were performed. A two-sided p value of
\0.05 was considered statistically significant.
Cardiovascular events were defined as cardiac disorders
at the system–organ–class term level for the purposes of
comparison of cardiovascular events across studies. The
Cochran–Mantel–Haenszel test was used to evaluate the
difference in the overall cardiovascular event rates between
the two cohorts after stratifying the data for baseline HbA1c
cohort, study, and anti-hyperglycemia concomitant therapy
use (yes or no).
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Results
Of the 18 studies reviewed, 11 studies did not meet
inclusion criteria and were not included in the meta-anal-
ysis (Fig. 1). Of these 11 studies, five consisted of patients
with type 1 diabetes as the study population, two were
extension studies of RCTs with type 1 diabetes population,
one was an extension of an included RCT such that the
patients were already included in the meta-analysis, one
had a treatment period of only 2 months, and two were
pharmacokinetic studies with no HbA1c measurements.
Therefore, a total of seven RCTs were identified to meet all
inclusion criteria and data from patients who were treated
with insulin lispro in these trials were included in the final
analysis.
Table 1 shows the characteristics of the seven studies
selected. Of these studies, three were randomized, parallel
group, open-label, active-controlled studies with insulin
lispro as one of two treatment arms with a treatment period
of 12 months [8, 9]. Both men and women with type 2
diabetes between the ages of 35 and 70 were enrolled in the
first two studies. Prior to enrollment, all patients used
commercially available human insulin for at least 2 months
and had achieved optimum compliance with their diabetic
diet and insulin therapy [8]. However, for the third study,
only patients with type 2 diabetes who had either not
received insulin or had received insulin for \2 months
prior to giving their informed consent were allowed to
enroll in the study and the study population involved a
wider age range (25–82 years) [9].
The fourth study was a randomized, two-period cross-
over, open-label, active-controlled study with two
treatment periods of 3 months each and involved patients
with type 2 diabetes who had been receiving human insulin
for at least 2 months prior to enrolling in this study [10]. At
Visit 1 of this study, patients were placed on Humulin R for
pre-meal insulin therapy and either Humulin N (NPH) or
Humulin U for basal insulin therapy for a 2- to 4-week
lead-in period [10]. The fifth study was not a cross-over
design but had two treatment periods (period 1 and 2) of
2 months each [11]. This randomized, open-label study
compared insulin lispro, sulfonylurea, and NPH insulin in
patients with type 2 diabetes who required treatment with
insulin after failure of an oral agent therapy. Data from
insulin lispro ? NPH and insulin lispro ? sulfonylurea
treatment groups from both treatment periods were inclu-
ded in the meta-analysis.
The sixth study was a randomized, open-label, two-arm
parallel study where each patient underwent a lead-in
period prior to randomization. This study consisted of an
initial 18-month treatment period followed by an extended
follow-up phase of up to 5 1/2 years, for a total potential
duration of treatment of up to 7 years [12]. Patients with
type 2 diabetes and acute myocardial infarction were ran-
domized to one of the two treatment strategies: one treat-
ment strategy that targeted postprandial glycemia
(administration of insulin lispro) and another that targeted
fasting/interprandial glycemia (administration of basal
insulin or biphasic intermediate-acting insulin). Only data
from patients randomized to the postprandial group were
used in the meta-analysis.
Similar to the fourth study, the seventh study was a
multicenter, randomized, open-label, two-period crossover
study consisting of an 8-week lead-in treatment with NPH
Fig. 1 Flow diagram of the
study selection process. HbA1c
hemoglobin A1c, PK
pharmacokinetic, T1DM type 1
diabetes, T2DM type 2 diabetes
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twice daily (BID). Patients were then randomized to
receive either pre-meal insulin lispro ? bedtime NPH or
NPH BID for 3 months each [13]. Data from patients
receiving insulin lispro ? NPH during period 1 were used
in the current analysis. The various definitions of hypo-
glycemia used in the trials included in the meta-analysis
are presented in Table 2.
Patient disposition and baseline characteristics
A total of 1,525 patients from the ‘‘all-studies combined’’
dataset were included in the analysis, of which 885 patients
received treatment for up to 6 months (‘‘long-term studies
combined’’ dataset). In the ‘‘all-studies combined’’ analy-
sis, there were 1,084 (71 %) non-geriatric patients and 441
(29 %) geriatric patients. Approximately 94.3 % of non-
geriatric patients (1,022/1,084) and 91.6 % of geriatric
patients (404/441) completed at least 3 months of insulin
therapy. There were no statistically significant differences
in the reasons for discontinuation of a study between the
age cohorts, except for the reason of death (geriatric: 9
patients, 2.0 %; non-geriatric: 6 patients, 0.6 %;
p = 0.017). For the ‘‘long-term studies combined’’, a sig-
nificantly lower proportion of geriatric patients (84.6 %)
completed 6 months of their clinical study compared with
non-geriatric patients (90.7 %; p = 0.010). Statistical dif-
ferences between age cohorts were noted for ‘‘personal
conflict’’ or ‘‘other patient decision’’ as reasons for dis-
continuation (data not shown).
Table 3 presents the baseline characteristics of all
patients included in each analysis of ‘‘all-studies com-
bined’’ and ‘‘long-term studies combined’’. The majority of
the sample were males, but with an overall smaller pro-
portion of males in the geriatric cohort compared with the
non-geriatric cohort. A greater proportion of the geriatric
cohort was Caucasian compared with the non-geriatric
cohort. The mean duration of diabetes ranged from 8.5 to
12 years and was significantly greater for geriatric patients.
At baseline, HbA1c was significantly lower for the geriatric
cohort. Further, a smaller proportion of patients in the
geriatric cohort reported at least one previous episode of
hypoglycemia at the baseline visit. In addition, there was a
significantly lower mean baseline rate of hypoglycemia
episodes in the geriatric cohort compared with the non-
geriatric cohort. Mean BMI was similar for both age
cohorts.
Efficacy
The primary efficacy endpoint of non-inferiority of insulin
lispro treatment in the geriatric cohort as compared to the
non-geriatric cohort was achieved for both the ‘‘all studies
combined’’ and the ‘‘long-term studies combined’’ analyses
(Table 4). The mean change in HbA1c from baseline to
Month 3 was similar for patients in the geriatric cohort
(-0.97 %) and non-geriatric patients (-1.05 %), with an
LS mean difference (95 % CI) of 0.02 % (-0.11, 0.15 %;
p = 0.756). Since the lower limit of the 95 % CI was
greater than -0.4 %, non-inferiority was demonstrated.
Basal insulin use was not a significant factor and similar
treatment comparison results were observed when patients
with HbA1c values defined as outliers (\4.5 % or [15 %)
were excluded.
The mean change in HbA1c from baseline to Month 6
was similar between the age cohorts (geriatric: -0.96 %;
non-geriatric: -1.16 %), with an LS mean difference
(95 % CI) of 0.07 % (-0.12, 0.26 %; p = 0.490). The
mean daily insulin lispro dose was similar for the two age
cohorts both at Month 3 (geriatric: 0.39 unit/kg; non-
geriatric: 0.38 unit/kg, p = 0.648) and Month 6 (geriatric:
0.45 unit/kg; non-geriatric: 0.42 unit/kg, p = 0.676).
Figure 2 shows the LS mean differences of HbA1c level
from baseline to Month 3 (upper panel) and Month 6
(lower panel). There were no significant differences
Table 2 Definition of hypoglycemic episodes according to individual studies
Category Definitions
Hypoglycemic episodes Any time a patient felt that he or she was experiencing a sign or symptom that he or she associated with hypoglycemia,
or a blood glucose measurement of\2.0 mmol/L (36 mg/dL). No definition of severe or serious hypoglycemia was
included in the protocol, but characteristics of each episode were collected [8]
A patient experiencing signs/symptoms of hypoglycemia and/or accompanied by a fingerstick glucose \63 mg/dL
(3.5 mmol/l) even if it is not associated with signs, symptoms, or treatment [9, 10, 12, 13]




Severe hypoglycemia was defined when assistance from another individual is required because it is disabling, i.e., any
episode where the patient is in a coma or requires a glucagon or intravenous glucose injection [13]
Severe hypoglycemia was defined as fingerstick glucose \50 mg/dL (2.8 mmol/l) [12]
Serious hypoglycemia was defined when the episode resulted in coma or required treatment with a glucose or glucagon
injection [11]
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Table 3 Summary of patient characteristics at baseline









Age, mean years (SD) 54.19 (7.32) 70.49 (4.11) \0.001 54.23 (7.22) 70.85 (4.18) \0.001
Males, n (%) 649 (59.9) 230 (52.2) 0.006 401 (64.2) 132 (50.8) \0.001
Race/regional origin (%)a
Caucasian 82.6 93.4 78.7 93.5
Western Asian 7.1 1.8 10.9 2.7
African descent 4.3 2.3 \0.001 4.8 1.9 \0.001
Hispanic 3.0 0.7 3.0 0.8
East/Southeast Asian 0.5 0.7 0.3 0
Other 2.5 1.1 2.2 1.2
Body weight (kg)
Mean (SD) 82.43 (16) 78.02 (14.10) \0.001 82.1 (15.29) 78.05 (13.18) \0.001
Body mass index (BMI)
Mean (SD) 28.77 (4.76) 28.41 (4.32) 0.173 28.64 (4.56) 28.56 (4.27) 0.814
Duration of diabetes (years)
Mean (SD) 9.30 (6.89) 12.33 (8.11) \0.001 8.53 (6.76) 11.70 (8.24) \0.001
Baseline HbA1c (%)
Mean (SD) 9.06 (1.68) 8.77 (1.65) 0.002 8.83 (1.62) 8.40 (1.46) \0.001
Baseline incidences of hypoglycemia (%)
None 70.5 79.9 \0.001 80.0 87.7 0.007
At least 1 in pre-study assessment 29.5 20.1 20.0 12.3
Baseline rate of hypoglycemia (episodes
per 30 days, mean (SD))
Overall 1.66 (3.89) 1.10 (3.30) 0.006 1.03 (0.00) 0.64 (0.00) 0.050
Means were analyzed using a 2-sample t test for age, body weight, BMI, duration of diabetes, and baseline HbA1c data
Frequencies are analyzed using Fisher’s exact test for gender, race, and baseline incidences of hypoglycemia data
p values were calculated using a ranked ANOVA model to analyze the rate of hypoglycemic episodes per 30 days with age group being the
covariate
a Significantly different between the two age cohorts
Table 4 Changes in HbA1c levels from baseline in type-2 diabetes patients treated with insulin lispro










Non-geriatric 9.07 (1.69) 8.03 (1.38) -1.05 (1.49) -0.96 (0.10) 8.85 (1.64) 7.68 (1.34) -1.16 (1.69) -1.13 (0.12)
Geriatric 8.82 (1.66) 7.85 (1.23) -0.97 (1.29) -0.94 (0.08) 8.44 (1.49) 7.48 (1.17) -0.96 (1.38) -1.20 (0.15)
Age group
comparisonb
LS mean difference (95 % CI) 0.02 (-0.11, 0.15) LS mean difference (95 % CI) 0.07 (-0.12, 0.26)
LS mean difference (p value) 0.756 LS mean difference (p value) 0.490
LOCF last observation carried forward, n number of patients included in the analysis
a Patients who had only baseline values or those who did not have any baseline values were not included in this analysis. Data are shown as mean
(SD) unless otherwise noted
b The ANCOVA model included age cohort, basal insulin use, baseline HbA1c, country cohort, and study. Age cohort by baseline HbA1c and age
cohort by study were not included in the model as these were not statistically significant factors
Aging Clin Exp Res (2014) 26:77–88 83
123
between the two age cohorts across the individual studies
included in the meta analyses.
Hypoglycemia
No statistically significant differences were noted in the
incidence of hypoglycemic episodes up to Months 3 and 6
between the two age cohorts (Table 5). The mean rate of
hypoglycemia was similar for geriatric as well as non-
geriatric patients (Month 3: 1.21 vs. 1.52 per 30 days
[p = 0.276]; Month 6: 0.71 vs. 1.01 per 30 days
[p = 0.234]). Analysis of the incidence of all patient-
reported hypoglycemic episodes as well as the rate of
hypoglycemia after adjusting for renal function also
showed no statistically significant differences between age
cohorts for ‘‘all-studies combined’’ and ‘‘long-term studies
combined.’’ The overall incidence of severe hypoglycemia
in 2 of the 7 studies that contained the definition was found
to be \5 % in both geriatric and non-geriatric cohorts;
however, the mean rate of severe hypoglycemia was sig-
nificantly greater in geriatric compared to non-geriatric
cohort up to Month 3 (0.02 and 0.00 per 30 days, respec-
tively; p = 0.009) and Month 6 (0.01 and 0.02 per 30 days,
respectively; p = 0.007 [data not shown in Table]). Fig-
ure 3 shows that there is no significant heterogeneity
(based on age by study interaction) in relation to the LS
mean ratio of hypoglycemic rates observed between geri-
atric and non-geriatric cohorts.
Cardiovascular safety
The relatively small number of overall cardiac events
(defined as cardiac disorders at the system–organ–class
term level) in the studies included in this meta-analysis, as
well as the short duration of the studies, precluded defini-
tive conclusions regarding the cardiovascular safety profile
of insulin lispro in geriatric versus non-geriatric patients.
Analysis of cardiovascular events by pre-existing condi-
tions at baseline for Months 3 and 6, based on Fisher’s
exact test, showed that a significantly greater proportion of
geriatric patients had a previous cardiovascular event
compared with non-geriatric patients (Month 3: 43.1 vs.
25.4 %, respectively [p \ 0.001]; Month 6: 52.7 vs.
31.8 %, respectively [p \ 0.001]). However, no statisti-
cally significant differences were noted between the geri-
atric and non-geriatric cohorts in the proportion of patients
Fig. 2 LS mean difference of the change in HbA1c from meta-analysis by study (non-geriatric minus geriatric)
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who developed a cardiovascular event after baseline
(Month 3: 7.3 vs. 5.4 %, respectively [p = 0.152]; Month
6: 14.2 vs. 11.2 %, respectively [p = 0.214]) or in the
percentage of patients with cardiovascular events at base-
line having increased severity of that event during the study
(Month 3: 0.5 vs. 0.6 %, respectively [p [ 0.999]; Month
6: 0 vs. 1.0 %, respectively [p = 0.188]). Analysis of
cardiovascular events at preferred term level up to Months
3 and 6 by the following strata: anti-hyperglycemia con-
comitant therapy use (yes/no); baseline HbA1c cohort (\7,
7–8, 8–9, 9–10, [10 %); or study, showed no statistical
differences between the two age cohorts based on Coch-
ran–Mantel–Haenszel test.
Serious adverse events
Overall, a similar percentage of patients experienced at
least one serious adverse event (SAE) across the two age
cohorts at month 3 (geriatric: 34 patients, 7.7 %; non-
geriatric: 60 patients, 5.5 %; p = ns) and month 6 (geri-
atric: 27 patients, 10.4 %; non-geriatric: 51 patients, 8.2 %;
p = ns). Infection and infestations was the only classifi-
cation that reached statistical significance in the geriatric
cohort compared with non-geriatric at month 3 (geriatric: 6
patients, 1.4 %; non-geriatric: 2 patients, 0.2 %;
p = 0.009) and at month 6 (geriatric: 6 patients, 2.3 %;
non-geriatric: 3 patients, 0.5 %; p = 0.022). There was no
Table 5 Incidence and rate of hypoglycemic episodes
All studies combined (up to month
3)











Overall incidence of hypoglycemic episodes,
n (%)
659 (60.79) 241 (54.65) 0.828 368 (58.88) 131 (50.38) 0.941
Overall rate of hypoglycemic episodes per 30
days, mean (SD)
1.52 (2.81) 1.21 (2.47) 0.276 1.01 (1.99) 0.71 (1.67) 0.234
Fig. 3 LS mean ratios of hypoglycemia rates from meta-analysis by study (non-geriatric vs. geriatric)
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difference in the rates of malignancy/neoplasms between
the two cohorts at both Months 3 and 6.
Other safety analyses
At Month 3, the most frequently reported (C2 %) treatment
emergent adverse events (TEAEs) for geriatric patients
included (in order of decreasing frequency): headache,
nasopharyngitis, peripheral odema, arthralgia, cough, and
dyspnoea. A significantly lower proportion of geriatric
patients had at least one TEAE compared with non-geri-
atric patients at Month 3 (geriatric: 212 patients, 48.1 %;
non-geriatric: 646 patients, 59.6 %; p \ 0.001) and Month
6 (geriatric: 141 patients, 54.2 %; non-geriatric: 392
patients, 62.7 %; p = 0.020). In the 3-month analysis,
TEAEs occurring significantly more frequently in geriatric
patients as compared to non-geriatric patients included
arteriogram coronary (geriatric: 10 patients, 3.8 %; non-
geriatric: 9 patients, 1.4 %; p = 0.038) and hypoglycemia
(geriatric: 4 patients, 1.5 %; non-geriatric: 1 patient, 0.2 %;
p = 0.028). In addition, diabetic retinopathy was reported
more frequently in geriatric patients compared to non-
geriatric patients (geriatric: 7 patients, 1.6 %; non-geriat-
ric: 5 patients, 0.5 %; p = 0.048).
At Month 6, the most frequently reported (C2 %) TE-
AEs for geriatric patients were arteriogram coronary,
headache, nasopharyngitis, diabetic retinopathy, anemia,
bronchitis, dizziness, and rhinitis. TEAEs occurring sig-
nificantly more frequently in geriatric patients as compared
to non-geriatric patients at Month 6 included arteriogram
coronary (geriatric: 10 patients, 3.8 %; non-geriatric: 9
patients, 1.4 %; p = 0.038) and hypoglycemia (geriatric: 4
patients, 1.5 %; non-geriatric: 1 patient, 0.2 %;
p = 0.028).
Discussion
Insulin therapy remains underutilized in geriatric popula-
tions despite the fact that many geriatric patients with a
history of type 2 diabetes could benefit from the use of
insulin to achieve improved glycemic control [14]. This
meta-analysis of seven randomized controlled clinical trial
data showed non-inferiority in the efficacy of insulin lispro
for geriatric patients compared with non-geriatric patients.
Despite the heterogenic nature of the seven RCTs analyzed,
the mean changes in HbA1c from baseline to Months 3 and
6 were similar for geriatric and non-geriatric patients
treated with insulin lispro, and the decrease in HbA1c was
associated with the same dose of insulin lispro across both
age cohorts.
To date, clinical evidence on achieving maximal gly-
cemic control with minimal adverse effects in geriatric
subjects is scarce [15, 16]. Published guidelines for man-
aging diabetes in geriatric patients are also not entirely
evidence-based; instead, they are often based on the clin-
ical experiences of the expert panel involved in developing
the guidelines [17]. A recent study comparing insulin
regimens of geriatric and non-geriatric patients in actual
clinical practice reported a discrepancy between practice
and guideline recommendations [18]. The authors of this
study noted that geriatric subjects were more commonly
treated with simple regimens involving greater use of basal
insulin instead of fast-acting insulin. The time-action pro-
files of rapid-acting insulin have been shown to better
mimic the physiological response of endogenous insulin to
food intake compared with regular human insulin [18–20].
As a result, some reports suggest that the rapid-acting
insulin analogs may be well-suited for optimal glycemic
control in geriatric populations [16, 20–22]. Our current
findings support the contention that the rapid-acting insulin
analog insulin lispro is as effective in achieving glycemic
control in geriatric patients as it is in non-geriatric patients
with type 2 diabetes at a similar dose.
Due to the potential for adverse effects, safety consid-
erations with glycemic control are always crucial in the
management of diabetes. Hypoglycemia is the most fre-
quent undesirable effect of insulin therapy. Obtaining
optimal glycemic control while preventing hypoglycemia
is a particular challenge clinicians face when treating
geriatric patients, partly due to the difficulty in predicting
the timing of peak insulin action [21]. Because frail geri-
atric patients (distinguished from autonomous patients free
of serious co-morbidity using evaluation scales validated
for geriatric patients) are particularly at increased risk for
hypoglycemia, especially with aggressive therapeutic
goals, many guidelines (as reviewed by Constans [17])
recommend distinguishing frail patients from patients free
of comorbidity prior to establishing treatment goals. The
fear of hypoglycemia also tends to make some patients
accept suboptimal glycemic control. While our current
analysis did not distinguish between frail versus non-frail
patients within the geriatric population, our analysis dem-
onstrates that insulin lispro was effective in improving
glycemic control in geriatric patients with similar incidence
and rate of hypoglycemia as compared to non-geriatric
patients.
Also, the incidence of severe hypoglycemia is reported
to be higher in geriatric patients compared with younger
patients when treated with insulin alone [18]. Since no
cases of severe hypoglycemia were reported in one of the
two studies containing the definition [13], our analysis of
severe hypoglycemia was limited to data from just one
study that included only patients with a documented history
of acute myocardial infarction [12]. Although the overall
incidence of severe hypoglycemia was low in the current
86 Aging Clin Exp Res (2014) 26:77–88
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analysis, a statistically significant greater proportion of
patients in the geriatric cohort had at least one episode of
severe hypoglycemia compared with non-geriatric patients.
As reported in the literature, it is not an uncommon
observation to find an increased frequency of severe
hypoglycemia in geriatric patients [23–29]. Indeed, in a
study analyzing data from two recent cross-sectional sur-
veys, nearly 10 % of the study population was reported to
have had an event of severe hypoglycemia at least once a
year [28], and more frequently in patients with consider-
able comorbidity undergoing aggressive diabetes manage-
ment [25]. Although flexibility of glycemic goals is being
contemplated in the recently updated ADA guidelines
(2012), and has been considered as a reasonable approach
in trying to reduce the overall risk of hypoglycemia in
geriatric populations [30], the study reporting severe
hypoglycemia [12] was conducted with a goal of achieving
and maintaining HbA1c\7 % as per the ADA guidelines at
that time.
As shown in the literature, a great number of hypogly-
cemic episodes (including severe hypoglycemia) may be
avoided by educating patients on the principles of blood
glucose monitoring, by involving general practitioners in
outpatient management of diabetes, and by close moni-
toring of hypoglycemia [25, 26, 31]. Our current meta-
analysis demonstrates that geriatric patients can be treated
safely with insulin lispro, with no age-related differences in
either the rate or the incidence of overall hypoglycemia.
Our current study has some limitations. The primary
limitation is that the data analysis was retrospective and
included only patients with type 2 diabetes. Therefore, the
results may not be generalizable to the entire geriatric
patient population with diabetes, including type 1 diabetes.
Also, the studies included in the meta-analysis were rela-
tively short-term and had sample sizes too small to draw
conclusions relative to cardiovascular events. Analyses of
hypoglycemic episodes were based on the respective defi-
nitions of hypoglycemic episodes used in the individual
studies, which were inconsistent across the seven studies
analyzed. This inconsistency may have resulted in hypo-
glycemic episodes being captured in some studies, but not
in others, thus making it difficult to compare hypoglycemia
across studies. In addition, the interaction between kidney
function and hypoglycemia could not be assessed based on
the GFRs and plasma creatinine levels. Instead, the inci-
dences of hypoglycemia were reported after adjusting renal
function status.
In conclusion, the results of this retrospective meta-
analysis suggest that geriatric patients with type 2 diabetes
can be treated with insulin lispro to achieve the same level
of metabolic control as in non-geriatric patients. The gen-
eral safety profile relating to hypoglycemia was similar in
the two age cohorts; thus, suggesting that insulin lispro is a
safe and effective treatment option for the geriatric
population.
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